Related Experiment Video
Updated: May 16, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer
Tzu-Yin Lin1, Yuan-Pei Li, Hongyong Zhang
1Division of Hematology & Oncology, Department of Internal Medicine, School of Medicine, University of California-Davis, Sacramento, CA 95817, USA.
Aim:
This work aimed to determine if the treatment outcomes of bladder cancer could be improved by targeting micelles that are decorated with bladder cancer-specific ligands on the surface and loaded with the chemotherapeutic drug paclitaxel.
Materials & Methods:
Targeting efficacy and specificity was determined with cell lines. An in vivo targeting and anti-tumor efficacy study was conducted in mice carrying patient-derived xenografts.
Results & Discussion:
Targeting micelles were more efficient than nontargeting micelles in delivering the drug load into bladder cancer cells both in vitro and in vivo (p < 0.05). The micelle formulation of paclitaxel was less toxic than free paclitaxel in Cremophor(®) (Sigma, MO, USA) and allowed administration of three-times the maximum tolerated dose without increasing the toxicity. Targeting micelles were more effective than the nontargeting micelles in controlling cancer growth (p = 0.0002) and prolonging overall survival (p = 0.002).
Conclusion:
Targeting micelles loaded with paclitaxel offer strong potential for clinical applications in treating bladder cancer.
Insights
Targeted paclitaxel-loaded micelles significantly improved bladder cancer treatment outcomes. These targeted micelles demonstrated enhanced drug delivery, reduced toxicity, and superior anti-tumor efficacy compared to non-targeted micelles.
Area of Science:
- Nanotechnology in oncology
- Drug delivery systems
- Bladder cancer therapeutics
Background:
- Bladder cancer remains a significant health concern requiring improved treatment strategies.
- Chemotherapy, while effective, often suffers from systemic toxicity and limited efficacy.
- Targeted drug delivery systems offer a promising approach to enhance therapeutic outcomes and minimize side effects.
Purpose of the Study:
- To evaluate the efficacy of paclitaxel-loaded micelles targeted to bladder cancer cells.
- To assess the in vitro and in vivo targeting specificity and anti-tumor activity of these novel micelles.
- To compare the toxicity profile of targeted micelles with free paclitaxel.
Main Methods:
- Development of micelles decorated with bladder cancer-specific ligands and loaded with paclitaxel.
- In vitro assessment of targeting efficacy and specificity using bladder cancer cell lines.
- In vivo studies in mice with patient-derived xenografts to evaluate tumor targeting and anti-tumor efficacy.
Main Results:
- Targeted micelles showed significantly higher drug delivery efficiency into bladder cancer cells compared to non-targeted micelles (p < 0.05).
- The micelle formulation of paclitaxel exhibited reduced toxicity, allowing for administration of a higher dose than free paclitaxel.
- Targeted micelles demonstrated superior control of tumor growth (p = 0.0002) and prolonged overall survival (p = 0.002) in vivo.
Conclusions:
- Targeted paclitaxel-loaded micelles represent a promising strategy for enhanced bladder cancer treatment.
- This formulation offers improved drug delivery, reduced toxicity, and significant anti-tumor effects.
- The results suggest strong potential for clinical translation in managing bladder cancer.
